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Ovarian cancer is the leading cause of gynecological 
disease death despite advances in medicine. Therefore, 
novel strategies are required for ovarian cancer ther-
apy. Conditionally replicative adenoviruses (CRAds), 
genetically modified as anti-cancer therapeutics, are 
one of the most attractive candidate agents for cancer 
therapy. However, a paucity of coxsackie B virus and 
adenovirus receptor (CAR) expression on the surface 
of ovarian cancer cells has impeded treatment of ovar-
ian cancer using this approach.  
 This study sought to engineer a CRAd with en-
hanced oncolytic ability in ovarian cancer cells, 
“Δ24DoubleRGD.”  Δ24DoubleRGD carries an argin-
ine-glycine-aspartate (RGD) motif incorporated into 
both fiber and capsid protein IX (pIX) and its oncolytic  
efficacy was evaluated in ovarian cancer. In vitro 
analysis of cell viability showed that infection of ovar-
ian cancer cells with Δ24DoubleRGD leads to in-
creased cell killing relative to the control CRAds. Data 
from this study suggested that not only an  increase in 
number of RGD motifs on the CRAd capsid, but also a 
change in the repertoir of targeted integrins could lead 
to enhanced oncolytic potency of Δ24DoubleRGD in 
ovarian cancer cells in vitro. In an intraperitoneal 
model of ovarian cancer, mice injected with 
Δ24DoubleRGD showed, however, a similar survival 
rate as mice treated with  control CRAds. 
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model 
Introduction 
 
Ovarian cancer is the leading cause of gynecologic 
disease death (Jemal et al. 2008). In 2009 there were 
approximately 21,990 new cases of ovarian cancer and 
15,460 deaths from this disease in the United States 
alone (NCI 2009). Traditional treatments have im-
proved over the past several decades, but the 5-year 
survival rate of women diagnosed with ovarian cancer 
remains below 50% (Choi et al. 2008). To improve the 
outcomes achieved using ovarian cancer therapy, novel 
treatment regimen and modalities have been proposed 
in the past several years. One such novel treatment 
involves the use of conditionally replicative adenovi-
ruses (CRAds) as cancer therapeutic agents (Barnes et 
al. 2002). Several considerations must be taken into 
account for effective use of CRAds: 1) selective infec-
tion of cancer cells versus non-cancer cells, 2) specific 
killing of cancer cells versus normal cells, and 3) in 
vivo stability of the virus. 
 Wild type adenovirus (Ad) infections cause a natu-
ral cytolytic effect on target cells, resulting from viral 
replication that leads to cell destruction. Newly re-
leased progeny particles then laterally spread to and 
infect adjacent target cells in repetitive cycles, leading 
to gradual destruction of infected tissue (Kirn 2000). 
CRAds, oncolytic Ads, can be generated through ma-
nipulation of the Ad genome. These manipulations 
allow preferential replication of the virus in cancer 
cells, and as a result, Ad viruses selectively kill cancer 
cells via their naturally lytic replication cycle (Heise et 
al. 2000, Heise & Kirn 2000). The utility of CRAds 
has been underscored by their rapid transition to clini-
cal trials. One type of CRAd was developed by means 
of deleting 24 base pairs (bps) from the immediate 
early E1A gene of the viral genome (Fueyo et al. 
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2000). This CRAd, known as “delta-24” (Δ24), fails to 
replicate in non-cancer cells because the deletion dis-
rupts the ability of E1A to bind to tumor suppressor 
retinoblastoma protein, Rb (Fueyo et al. 1996) . This 
function of E1A is critical for initiation of Ad DNA 
replication in normal cells, because the binding of E1A 
to Rb is required to overcome the G1-S checkpoint 
(Nevins 1992, Whyte et al. 1988, 1989). However, the 
24-bp deficiency is overcome in many cancer types 
(Sherr 1996), including ovarian cancer (Liu et al. 
1994,Yaginuma et al. 1997, Niederacher et al. 1999), 
due to disruption of the p16/Rb pathway. As a conse-
quence, Δ24CRAd replication occurs in a cancer-
selective manner in ovarian cancer cells. 
 Ovarian cancer cells have been found to express 
variable and often reduced levels of coxsackie B virus 
and adenovirus receptor (CAR), the primary receptor 
for Ad serotype 5 (Ad5), resulting in inefficient adeno-
virus transduction (Kelly et al. 2000,Vanderkwaak  et 
al. 1999, Khuu et al. 1999). However, αvβ integrins, 
have been shown to be expressed in abundance on 
ovarian cancer cells (Liapis et al. 1997, Cannistra et al. 
1995). Therefore, tropism modification strategies have 
been employed to increase infectivity of ovarian can-
cer cells. In particular, insertion of a ligand with an 
arginine-glycine-aspartate (RGD) motif in the HI loop 
of the fiber knob domain allows the Ad vector to effec-
tively target ovarian cancer cells through the RGD mo-
tif (Dmitriev et al. 1998, Bauerschmitz et al. 2002). 
One advantage of RGD-modified Ad vectors is that 
they have been determined to be more resistant to Ad5
-neutralizing antibodies in vivo than the unmodified 
vector (Wang et al. 2005). Moreover, a CRAd contain-
ing a fiber-incorporated RGD motif, Ad5-Δ24RGD, 
demonstrates increased infectivity in ovarian cancer 
cells (Suzuki et al. 2001), resulting in effective killing 
of those cells (Whyte et al. 1989). Furthermore, Ad5-
Δ24RGD shows an excellent safety profile in cotton 
rats (Page et al. 2007) and was recently evaluated in a 
Phase I trial for patients with recurrent ovarian cancer 
(Kimball et al. 2010). Thus, RGD-mediated transduc-
tion of Ad appears to be effective for targeting ovarian 
cancer. Based on these observations, we reasoned that 
further modification of Ad5-Δ24RGD (herein referred 
to as ∆24FiberRGD) could improve oncolytic potency 
and possibly therapeutic efficacy by augmenting its 
ability to bind to integrins on ovarian cancer cells. 
 Protein IX biochemical and structural localization 
studies have demonstrated that the C-terminus of this 
protein can efficiently present ligands genetically fused 
to it without detrimentally affecting the capsid assem-
bly and the viral infectivity. Ability of ligand-modified 
pIX to mediate Ad transduction has also been reported 
(Dmitriev et al. 1998, Meulenbroek et al. 2004, Vel-
linga et al. 2004, Dmitriev et al. 2002, Campos et al. 
2004). Based on these data, we hypothesized that si-
multaneous incorporation of the RGD motif in pIX and 
Fiber would enhance Ad infectivity and cell killing 
activity. Therefore, we genetically modified the C-
terminus of the pIX gene of Δ24RGD with the nucleo-
tide sequence for an RGD motif to generate 
Δ24DoubleRGD which contains the RGD motif in 
both pIX and Fiber, yielding a virus expressing up to 
276 (240 pIXs + 36 fibers) copies of the RGD-ligand. 
We examined the biological and physical properties of 
Δ24DoubleRGD and evaluated its oncolytic ability in 
vitro and in vivo. Due to its ability to induce oncolysis 
of ovarian cancer cells in vitro and in vivo to an extent 
similar to or greater than Δ24FiberRGD, we believe 
the Δ24DoubleRGD may be useful as a potential ovar-
ian cancer therapeutic.  
 
Materials and Methods 
 
Cells 
Human embryonic kidney 293 (HEK293) cells (CRL 
1573) and human lung epithelial A549 cells (ATCC 
CCL 185) were purchased from American type culture 
collection (ATCC, Manassas, VA). HEK293 cells and 
A549 cells were used for production and amplification 
of viruses, respectively. SKOV3.Luc cells were a kind 
gift from Dr. Robert Negrin (Stanford Medical School, 
Stanford, CA). The human ovarian cancer cell line, 
SKOV3.Luc, which stably expresses luciferase, was 
used for in vitro and in vivo experiments. Cells were 
maintained in DMEM/F-12 (Sigma-Aldrich; St. Louis, 
MO) supplemented with the following: 10% Fetal Bo-
vine Serum (FBS; Invitrogen Carlsbad, CA), 2 mM L-
glutamine (Sigma), 100 IU/ml penicillin (Sigma) and 
100 μg/ml streptomycin (Sigma). Cells were incubated 
in humidified atmosphere in 5% CO2 at 37˚C. The ade-
novirus-infected cells were cultured in the same me-
dium containing 2% FBS. 
 
Recombinant plasmids  
To construct the pShuttle plasmid needed to create the 
p Δ 2 4 I X F l a g 4 5 Å R G D  a n d 
pΔ24IXFlag45ÅRGDFiberRGD genomes (rescue vec-
tors) we replaced the tk portion of the 
pSlΔ24pIXNheFlag-tk (Kimball et al. 2009), with 
45ÅRGD, which was PCR-amplified from previously 
constructed pSlΔE1/CMV-luc,45ÅRGD shuttle plas-
mid (Borovjagin et al., unpublished data). The  
pSlΔ24IXFlag45ÅRGD shuttle vector and the 
pTG3602 backbone (Chartier et al. 1996) were di-
gested with PmeI and ClaI, respectively, and were sub-
jected to homologous recombination in Escherichia 
coli (E. coli) strain BJ5183 (Stratagene, La Jolla, CA). 
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The resulting vector, pΔ24IXFlag45ÅRGD, was used 
to generate Δ24IXRGD virus with wt fiber as a con-
trol. 
 To construct pΔ24IXFlag45ÅRGDFiberRGD, 
pSlΔ24IXFlag45ÅRGD shuttle vector was recombined 
with the pVK503C backbone plasmid (Dmitriev et al. 
1998), which contains a modified (DAM methylation-
proof) ClaI site in the E1 region and the RGD4C modi-
fication in the fiber knob HI-loop sequence. The shut-
tle vector and backbone plasmid were digested with 
PmeI and ClaI, respectively, and were homologously 
recombined in BJ5183. The resulting plasmid, 
pΔ24IXFlag45ÅRGDFiberRGD was used to generate 
Δ24DoubleRGD.  This sequence has been deposited 
into GenBank and the accession number is JF745946. 
 
Adenoviruses 
Plasmids pSlΔ24IXFlag-45ÅRGD and pSlΔ24IXFlag-
45ÅRGDFiberRGD, were digested with PacI, and 
transfected into HEK293 cells in a 25cm2 flask using 
Lipofectamine 2000TM (Invitrogen) in order to gener-
ate Δ24IXRGD and Δ24DoubleRGD, respectively. 
The transfected cells were incubated for approximately 
two weeks until full cytopathic effect (CPE) was in-
duced by the recombinant CRAds. After observation 
of CPE, we collected infected cells with medium and 
harvested by centrifugation at 3,000 × g for 5 minutes 
(min) at 4˚C. The cell pellet was resuspended in 5 ml 
of medium, and disrupted using four freeze and thaw 
cycles to release virus into the medium. Cell debris 
was removed by centrifugation at 3,000 × g for 5 min 
at 4°C, and the supernatant was used to scale up ade-
noviruses. 
 We also used two other CRAds, Δ24Ad5 
(Δ24) (Fueyo et al. 2000), and Ad5-Δ24RGD 
(Δ24FiberRGD) (Suzuki et al. 2001) to compare with 
Δ24DoubleRGD in this study. The Δ24Ad5 was kindly 
provided by Dr. Juan Fueyo (The University of Texas, 
M.D. Anderson Center, Houston, TX). The 
Δ24FiberRGD was manufactured under Good Labora-
tory Practice (GLP) conditions at the Biopharmaceuti-
cal Development Program (SAIC-Frederick, Frederick, 
MD) with support from the National Cancer Institute 
Rapid Access to Intervention Development program.  
 
Purification and titration of adenoviruses 
Each of the CRAds were amplified at the University of 
Alabama at Birmingham according to previously es-
tablished protocols.  Briefly, CRAds were propagated 
in A549 cells up to 15 flasks of 175 cm2 and purified 
by double CsCl density gradient centrifugation fol-
lowed by dialysis against phosphate-buffered saline 
(PBS [pH 7.4]) containing 10% glycerol for purifica-
tion (Maizel et al. 1968). The infectious titer (PFU/ml) 
of each virus was determined by titration in 293 cells 
as previously described (Borovjagin et al. 2010). The 
particle titer (vp/ml) was determined by A260 absorb-
ance of purified particles and assuming that 1.1 × 1012 
vp/ml has an absorbance of 1.0 at 260 nm, as previ-
ously described (Maizel et al. 1968). All viruses were 
stored at -80˚C until use. 
 
Sequencing  
All viruses were verified by sequencing provided by 
the Center for AIDS Research (CFAR) and Compre-
hensive Cancer Center (CCC) DNA Sequencing and 
Analysis Core at the University of Alabama at Bir-
mingham according to previously established proto-
cols. 
 
Western Blot Analysis 
Samples containing 5.0 × 109 vp of purified virus were 
boiled in Laemmli sample buffer for 5 minutes and 
analyzed by a 4 to 15% gradient sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Separated proteins were transferred to polyvinylidene 
difluoride (PVDF) membrane. PVDF membrane was 
blocked in 5% skim milk in Tris-buffered saline (pH 
7.5) containing 0.05% Tween 20 (TBST) followed by 
incubation with primary antibodies (mouse mono-
clonal anti-flag M2 primary antibody (Sigma) or 
mouse monoclonal anti-Fiber antibody [4D2] 1:5000 
(Thermo Scientific, Rockford, IL). The membranes 
were washed with TBST, blocked with TBST contain-
ing 5% skim milk, and incubated with the appropriate 
secondary goat anti-mouse antibodies conjugated with 
horse radish peroxidase (HRP) at 1:1000 dilution. The 
HRP signal was developed with ECL plus Western 
blotting detection system (GE healthcare, Little Chal-
font, UK) then detected with BioMax MR scientific 
imaging films (Kodak, Chalon-sur-Saone, France) us-
ing a medical film processor SRX-101A (Konica, To-
kyo, Japan). Pre-stained protein ladder of Kaleido-
scope Standard (Bio-Rad Laboratories, Inc.) was used 
to estimate protein sample sizes. 
 
Enzyme-linked Immunosorbent Assay (ELISA) 
αvβ3 or αvβ5 ELISA  
Purified αvβ3 or αvβ5 integrins (Millipore, Billerica, 
MA) were diluted in 50 mM bicarbonate buffer (pH 
9.5) to a final concentration of 1 µg/ml, and 200 µl 
aliquots were added to each well of a 96-well Nunc-
Maxisorp ELISA plate (Nunc Maxisorp, Rochester, 
NY). Plates were incubated for 2 hours at room tem-
perature to bind purified αvβ3 or αvβ5 integrins on the 
wells then washed four times with 200 μl of wash 
buffer (PBS containing 0.1% Tween 20; PBST). Sam-
ples were blocked for 1 hour at room temperature by 
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the addition of 100 μl blocking buffer (washing buffer 
containing 3% bovine serum albmin). The plate was 
incubated for 2 hours at room temperature to allow 
CRAds to bind to integrins. The wells were washed 
three times with 200 μl PBST then blocked with 100 μl 
blocking buffer for 1 hour at room temperature. Next 
we added anti-Ad5 sera (recovered from mice exposed 
to Ad) as a primary antibody to each well at a ratio of 
1:100 in 100 µl blocking buffer, and incubated the 
plate for 2 hours at room temperature. The wells were 
washed three times with 200 μl of PBST then blocked 
with 100 μl blocking buffer for 1 hour at room tem-
perature. Polyclonal goat anti-mouse antibody conju-
gated with HRP (Dako, Denmark, A/S) at 1:2000 dilu-
tion in blocking buffer was added for 2 hours at room 
temperature, followed by addition of 100 μl of Sig-
maFast OPD solution in 20 ml of deionized water 
(Sigma). Plates were incubated for 1 hour at room tem-
perature, and colorimetric changes were read at OD405 
nm using a 96-well plate reader (PowerWave HT340, 
Biotek). Each virus-integrin interaction was repeated 
in three wells and results are displayed as one point on 
a graph with bars indicating standard error.  
 
Flag ELISA  
Viruses were added to a Nunc-Maxisorp ELISA plate 
at the indicated concentrations. The plate was incu-
bated for 2 hours at room temperature to allow CRAds 
to bind to plate. The wells were washed three times 
with 200 μl PBST then blocked with 100 μl blocking 
buffer for 1 hour at room temperature. Next we added 
anti-Flag antibody conjugated to HRP at a ratio of 
1:1000 in blocking buffer and incubated at room tem-
perature for 2 hours. The wells were washed three 
times with 200 μl of PBST then 100 μl of SigmaFast 
OPD solution was added to each well. Plates were in-
cubated for 1 hour at room temperature, and colorimet-
ric changes were read at OD405 nm using a 96-well 
plate reader (PowerWave HT340, Biotek). Each virus-
integrin interaction was repeated in three wells and 
results are displayed as one point on a graph with bars 
indicating standard error. 
 
Analysis of cell viability by MTS Assay 
SKOV3.Luc cells were plated in a 96-well plate at 1 × 
104 cells per well and grown overnight. The following 
day, CRAds were diluted with medium containing 2% 
FBS, and cells were infected with Multiplicities of In-
fection (MOIs) of 0 (no virus), 0.1, 1.0, 10, 50, 100, or 
1,000 vp/cell. Infected cells were incubated for 10 
days. MTS assay was performed using the CellTiter 96 
AQueous One Solution Cell Proliferation Assay 
(Promega, Madison, WI) according to the manufac-
turer’s instructions. Colorimetric differences were 
measured at OD490 nm using a 96-well plate reader. 
Each MOI was repeated in three wells and data are 
displayed as one point on the graph with bars indicat-
ing standard error. Each experiment was performed 
three times and only one graph is displayed as a repre-
sentation of the data collected. 
 
Crystal Violet staining 
Crystal violet assay was used to determine the onco-
lytic effect of the CRAd agents on SKOV3.Luc cells 
following infection. We seeded 1 × 104 cells per well 
in 96-well plates, and incubated cells overnight. Cells 
were infected with CRAds at MOIs of 0 (no virus), 
0.1, 1.0, 10, 50, 100, or 1,000 vp/cell and incubated for 
10 days at 37˚C. On Day 10, medium was removed 
and infected cells were gently washed with PBS [pH 
7.4) and incubated with Crystal Violet solution (1% 
Crystal Violet in 70% ethanol) for 1 hour. Cells were 
washed three times with water then allowed to air dry 
overnight. We captured images of Crystal Violet solu-
tion staining levels with a JVC Everio HD digital cam-
era. 
  
Luciferase Assay 
We assessed cell viability using luciferase activity as a 
readout of remaining living cells following CPE induc-
tion by CRAds. We seeded 1.0 × 104 SKOV3.Luc 
cells/well in a 96-well plate and incubated overnight. 
Cells were infected with CRAds at MOIs of 0 (no vi-
rus), 0.1, 1.0, 10, 50, 100, or 1000 vp/cell for 10 days. 
Ten days post-infection, medium was aspirated and 
infected cells were gently washed with PBS (pH 7.4). 
Infected cells were lysed with 50 μl of passive lysis 
buffer (Promega, Madison, WI) for 15 minutes at 37˚C 
and the lysates were transferred to 1.5-ml tubes. 
Luciferase assay was performed according to the 
manufacturer’s protocol and the relative light unit 
(RLU) readout was normalized to the amount of pro-
tein present as determined by Dc protein assay 
(BioRad, Hercules, CA). Each MOI was repeated in 
three wells and data are displayed as one point on the 
graph with bar indicating standard error. Each experi-
ment was performed three times and only one graph is 
displayed as a representation of the data collected. 
 
Orthotopic ovarian cancer tumor model 
The University of Alabama at Birmingham Institu-
tional Animal Use and Care Committee approved the 
use of mice as described herein under the approved 
protocol number 090907606.  Seventy-five BALB/c 
nude mice, divided into five groups with 15 mice per 
group, were used for the orthotopic ovarian cancer 
model. SKOV3.Luc cells were cultured using tech-
niques described above then trypsinized and counted. 
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Trypan blue exclusion was used to determine that cell 
viability was > 98%. Cells were washed two times 
with PBS.  SKOV3.Luc cells (1×107) in 1000 µl of 
PBS were injected intraperitoneally (IP) into mice 6 
days prior to first injection with CRAd or PBS (Day -
6). CRAd (1×109 vp) or PBS was injected IP in 1000 
µl of PBS once per week for 3 weeks on Days 0, 7, and 
14.  Bioluminescent imaging of tumors was performed 
every 7 days. For imaging, 150 mg/kg luciferin 
(Xenogen Corporation, Alameda, CA) was injected IP 
into mice. After 10-20 minutes, mice were placed in 
the imaging chamber and maintained under anesthesia 
with 2% isoflurane gas (Minrane Inc., Bethleham, PA) 
at a flow rate of approximately 0.5-1.0 l/min per 
mouse (Highland Medical Equipment, Temecula, CA). 
Imaging was completed using a Xenogen IVIS 100 
camera ( Xenogen Corporation, Alameda, CA). Data 
were analyzed using Living Image software edition 3.1 
(Caliper Life Sciences, Hopkinton, MA). 
 
Statistical Analysis 
Statistical significance between groups was assessed 
using Student’s t-test calculations formulated for a two
-tailed analysis of two sets of data. A cutoff of P < 
0.05 was used to determine statistical significance. 
 
 
Results 
 
Confirmation of the integrity and viability of 
Δ24DoubleRGD 
Δ24DoubleRGD was generated as described in the 
Materials and Methods section. Direct sequencing of 
the purified CRAd genomes confirmed the nucleotide 
sequences of the RGD4C ligand inserted at both the 
fiber knob HI-loop and downstream of the pIX gene 
(data not shown). Figure 1 shows a schematic repre-
sentation of the CRAds used in this study. We first 
verified composition of the viral structural proteins 
using purified viral particles by coomassie blue stain-
ing. The viral structural proteins (Hexon, Penton base, 
and the doublet pIIIa and Fiber) of Δ24DoubleRGD as 
well as those of the control viruses were similarly 
stained by coommassie blue (Figure 2A). Therefore, 
modifications of pIX and fiber using the RGD motif 
did not appear to affect composition of the viral struc-
tural proteins. Western blot analysis of purified viral 
particles using anti-pIX antibody showed the presence 
of wild type pIX in ∆24Ad5 and ∆24FiberRGD virus 
particles at 14 kDa, which is the expected molecular 
weight of unmodified pIX (Figure 2B). Virus particles 
of ∆24IXRGD and ∆24DoubleRGD show, however, 
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Figure 1. Each of the CRAds used for these experiments contained a 24-bp deletion in the pRb-binding region of the immedi-
ate early gene (∆24). The virus that contains only this modification is ∆24Ad5. The modification at the gene encoding protein 
IX contains a fusion cassette that includes: Flag protein, a 45Ålinker, and the RGD4C motif. This fusion modification  was 
incorporated into the ∆24IXRGD. The Fiber modification incorporates the RGD4C motif in ∆24FiberRGD. The 
∆24DoubleRGD was engineered to incorporate both the fusion modification at pIX and the RGD4C motif at Fiber. 
bands that resolved at 21.8 kDa, which is the expected 
molecular weight of pIX and the fusion protein. A deg-
radation product (or possibly a protein band that cross-
reacts with the primary or secondary antibody) pIX-
RGD was detected in the Δ24DoubleRGD and 
Δ24RGD viral particles and marked with an asterisk 
(*). Western blot analysis of pIX presence in CRAds 
indicates differential weight of pIX in viruses corre-
sponding to fusion protein presence. Western blot 
analysis of purified viral particles using the Flag-
specific monoclonal antibody confirmed that the 21.8 
kDa band seen in the ∆24IXRGD and ∆24Double 
RGD samples contain the Flag epitope, a part of the 
fusion protein added to pIX (Figure 2C). In contrast, 
no protein was detected for Δ24Ad5 or Δ24FiberRGD 
due to lack of incorporation of the Flag-tag sequence 
into the pIX region of these CRAds. 
 Next, we confirmed quantitatively that pIX on 
the viral particles was modified by a fusion peptide 
containing the Flag epitope by ELISA assay using anti
-Flag antibody conjugated to HRP (Flag-HRP). ELISA 
analysis revealed Flag-HRP bound to Δ24IXRGD and 
Δ24DoubleRGD in a concentration-dependent manner, 
but not to Δ24Ad5 and Δ24FiberRGD (Figure 2D). 
This suggests Δ24IXRGD and Δ24DoubleRGD viral 
particles displayed the modified pIX protein. 
 Taken together, these data confirm the incor-
poration of normal proteins into the capsids of the 
newly created CRAds. Furthermore, the presence of 
the fusion protein containing: Flag, 45Å, and RGD 
motifs in the pIX region, was identified in both 
∆24IXRGD and ∆24DoubleRGD.  
 
Δ24DoubleRGD is capable of binding to αvβ3 and 
αvβ5 integrins 
We next assessed whether Δ24IXRGD or 
Δ24DoubleRGD viral particles interacted with αvβ3 
and αvβ5 integrins by ELISA. Figure 3A showed that 
both Δ24IXRGD and Δ24DoubleRGD effectively 
bound αvβ3 integrin in a dose-dependent manner. 
While Δ24Ad5 and Δ24FiberRGD had a lesser interac-
tion with αvβ3 integrin, both CRAds registered an inter-
action greater than 0. This is an expected result be-
cause each of the CRAds contain RGD in their penton 
base motifs which are known to interact with αvβ3.  
Δ24FiberRGD does bind αvβ3 better than Δ24Ad5. The 
binding of Δ24FiberRGD to αvβ3 is significantly 
greater than the binding of Δ24Ad5 to αvβ3 at concen-
trations greater than or equal to 12.5 × 108 vp/ml. For 
concentrations equal to or lower than 6.3 × 108 vp/ml 
there was no significant difference between the bind-
ing of Δ24Ad5 and Δ24FiberRGD to αvβ3; however, 
there was significantly more binding of both 
Δ24pIXRGD and Δ24DoubleRGD to αvβ3 than 
Δ24Ad5 at these same concentrations (Figure 3A). 
Δ24DoubleRGD, Δ24IXRGD, and Δ24FiberRGD each 
similarly recognized αvβ5 integrin in a dose-dependent 
manner (Figure 3B);the differences between binding of 
each of these CRAds to αvβ5 was not statistically sig-
nificant.  Binding of Δ24Ad5 to αvβ5 was significantly 
Figure 2. Coomassie stain verifies the presence of major 
Ad proteins: Hexon, Penton, and protein III and Fiber in 
each of the CRAds (A). pIX presence in each virus was 
verified by Western blot analysis (B). Flag incorporation 
into ∆24IXRGD and ∆24DoubleRGD was confirmed using 
Western blot analysis (C) and ELISA (D). Asterisks (*) 
indicate degradation products of the fusion protein in (B) 
and (C). 
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lower than binding of Δ24IXRGD, Δ24FiberRGD, and 
Δ24DoubleRGD at or above 6.3 × 108 vp/ml. The 
trend of greater binding of each of the CRAds to αvβ5 
versus Δ24Ad5 binding to αvβ5 continued throughout 
all of the concentrations. Notably, the binding of 
Δ24Ad5 to αvβ5 was above zero due to the presence of 
RGD on penton base interacting with αvβ5. 
 
Cell killing activity of Δ24DoubleRGD is enhanced 
as compared to Δ24FiberRGD in vitro 
To assess in vitro cell killing activity of 
Δ24DoubleRGD in ovarian cells, we performed crystal 
violet analysis. Crystal violet analysis using 
SKOV3.Luc cells demonstrated that cell killing activ-
ity of Δ24DoubleRGD was increased as compared to 
Δ24Ad5, Δ24IXRGD, and Δ24FiberRGD (Figure 4A). 
We also quantified cell killing activity of 
Δ24DoubleRGD as compared with the other CRAds 
using MTS assay. Δ24DoubleRGD showed similar cell 
killing ability to Δ24Ad5 and significantly better cell 
killing than Δ24IXRGD (p=0.0023) and 
Δ24FiberRGD (p=0.03) in ovarian cancer cells (Figure 
4B). The ability of Δ24DoubleRGD to kill ovarian 
cancer cells in vitro appeared to be unaffected by dou-
ble modification of pIX and Fiber. On the other hand, 
cell killing activity of Δ24IXRGD was attenuated, sug-
gesting that abnormal incorporation of the degradation 
product of pIX-RGD on the Δ24IXRGD viral particles 
observed in Figure 2B may affect its life-cycle in in-
fected cells. Taken together, these data demonstrated 
that Δ24DoubleRGD retains cell killing activity de-
spite genetic modifications and its cell killing ability is 
increased over the cell killing ability of Δ24IXRGD 
and Δ24FiberRGD. 
 
Δ24DoubleRGD shows oncolytic ability in vivo 
The indirect monitoring of death of cancer cells in-
fected with CRAds in an in vivo study is important 
because it enables progressive ante mortem readouts 
throughout the duration of an experiment. In this re-
gard, we have chosen to use luciferase-expressing 
ovarian cancer cells, SKOV3.Luc, in our animal 
model. Monitoring of luciferase stably-expressing can-
cer cells has been shown to facilitate detection of tu-
mor establishment in vivo (Contag et al. 2000). Indeed, 
the luciferase activity in tumor, as detected by biolumi-
nescence imaging, anatomically overlaps with tumor 
location in vivo (Edinger et al.1999). Before our in 
vivo study, we first confirmed whether luciferase activ-
ity in SKOV3.Luc cells infected with CRAds declines 
as CPE of these cells increases. After 10 days post-
infection, the remaining luciferase activity in 
SKOV3.Luc cells infected with Δ24DoubleRGD 
showed dramatic decrease as compared to that in non-
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Figure 3. ELISA analysis was used to validate the binding integrity of the CRAds used in this study. Integrins were bound to a 
96-well plate followed by binding of CRAds at the listed dilutions. Anti-Ad antibody followed by goat anti-mouse antibody 
conjugated to Horse Radish Peroxidase allowed for quantitative measurement of the amount of virus bound to integrins using a 
light-emitting reaction detectable by excitation at OD405. Both ∆24DoubleRGD and ∆24IXRGD bind αvβ3 integrin signifi-
cantly better than ∆24Ad5 and ∆24FiberRGD (A). Each of the RGD-modified CRAds bind αvβ5 significantly better than 
∆24Ad5 (B). 
replicative Ad-infected cells (Figure 5). Also, the re-
maining luciferase activity in SKOV3.Luc cells in-
fected with Δ24DoubleRGD was the lowest value 
among SKOV3.Luc cells infected with CRAds. The 
Δ24Double RGD showed increased cell killing versus 
Δ24Ad5 (p = 0.0009), Δ24IXRGD (p=0.04), and 
Δ24FiberRGD (p=0.019). These data support the 
trends produced by the previous data that 
Δ24RGDCRAd has increased oncolytic ability versus 
other CRAds (Figure 4) and suggests that luciferase 
activity may be used to indicate the relative amount of 
living cells remaining following CRAd infection. 
 Next we assessed the oncolytic potency of 
Δ24DoubleRGD in an orthotopic in vivo model of 
ovarian cancer. SKOV3.Luc cells were used to intrap-
eritoneally establish tumors in female nude mice. Mice 
were imaged 24 hours post-injection of cells (Day -5) 
to ensure appropriate cell injection (Figure 6A). On 
day 6 post-injection of cells (Day 0), mice were im-
aged to ensure viability of cells and similar expression 
between groups. Following segregation into groups, 
mice were injected with 1.0 ×109 vp of CRAds or PBS 
weekly on Days 0, 7, and 14. Representative images 
indicated that mice injected with Δ24DoubleRGD dis-
played less luciferase expression than mice treated 
with PBS beginning at day 21 post-injection (Figure 
6A). Quantitative expression of light units was deter-
mined by capture of light emitted from mice following 
injection with luciferin. Data in photons/second were 
collected and averaged per group of mice. Quantita-
tively, lower levels of bioluminescence in mice treated 
with Δ24DoubleRGD as well as each of the other 
CRAds were detected at 21 days post-injection as 
compared to mice treated with PBS (Figure 6B).  Mice 
treated with Δ24DoubleRGD survived longer than the 
PBS-treated group whose average lifespan was 23 days 
post-injection of PBS (Figure 6C). Thus, treatment 
with Δ24DoubleRGD as well as the other CRAds pro-
longed the survival of mice versus PBS-treated group 
in this experiment. The overall survival of the mice 
treated with either of the CRAds averaged 29.5 days. 
 
Discussion 
 
Novel treatments for ovarian cancer have been used in 
the past several years in an effort to increase the life-
span of ovarian cancer patients. Targeted therapy is 
one form of novel treatment that has gained much ex-
posure over the last decade due to its potential to selec-
tively deliver an oncolytic therapy to cancer cells while 
incurring minimal deleterious effects on non-cancer 
cells. In this regard, ovarian cancer is an ideal candi-
date for treatment with targeted therapy as it usually 
presents with metastases throughout the peritoneum of 
patients. Ovarian cancer is a good disease model for 
targeted therapy development because of the expres-
sion of a certain class of molecules on the surfaces of 
ovarian cancer cells in what has been discovered as a 
cancer-specific pattern. This class of molecules is in-
tegrins. Integrins belong to a family of cell surface re-
ceptors made up of 18-α and 8-β subunits that mediate 
attachment of cells to the extracellular matrix or other 
cells by combining to form at least 24 different het-
erodimers (Ruoslahti 1996, Hynes 1999). Integrins are 
expressed on many cell types and under physiological 
conditions are used to facilitate attachment between 
Figure 4. Crystal violet analysis of SKOV3.Luc cells fol-
lowing 10-days of infection with CRAds at listed VP/cell 
indicated that ∆24DoubleRGD causes more CPE, as deter-
mined by less staining of remaining cells, as compared to 
Ad5 non-replicative control vector, ∆24Ad5, ∆24IXRGD, 
and ∆24FiberRGD (A). ∆24DoubleRGD also caused in-
creased killing of SKOV3.Luc cells as determined by light 
emitted from cells following administration of MTS reagent 
and read on plate reader at OD405 (B). Less light emitted is 
indicative of increased CPE, less living cells, at the time of 
reading. 
(A) (B) 
33   Journal of Molecular Biochemistry, 2012 
the extracellular matrix or other cells (Ruoslahti 1996, 
Hynes 1999), as well as to support cell proliferation, 
migration, and viability (Carmeliet 2000, Friedlander 
et al. 1995).  The αv subunit of integrins is overex-
pressed on ovarian cancer cells (Liapis et al. 1997, 
Cannistra et al., 1995) and has been identified as a 
marker for poor prognosis in advanced-stage ovarian 
carcinoma (Goldberg et al. 2001). Furthermore, Liapis 
et al. (1997) report increased expression of αvβ3 in 
ovarian carcinomas as compared to tumors with low 
malignant potential. αvβ3 has been shown to be ex-
pressed in 6 of 9 ovarian cancer specimens and 50% of 
SKOV3 cells (the parent cell line of the SKOV3.Luc 
cells used in our study) in a study to determine the ex-
pression of integrins in ovarian carcinoma (Cannistra 
et al. 1995). Several experiments with conflicting re-
sults have also been published: β3 expression is associ-
ated with a favorable prognosis in ovarian cancer pa-
tients (Kaur et al. 2009) and Carreiras et al. (1996) 
reported that the β3 integrin is less highly expressed in 
high-grade versus well-differentiated tumors. These 
data indicate that variability of integrin expression on 
ovarian cancer cells is expected. Therefore, despite 
these conflicting data regarding amounts of receptors 
on certain types of ovarian carcinomas, we know that 
some expression of αvβ3 and αvβ5 integrins is evident 
in our SKOV3.Luc cells because the presence  of these 
integrins is a necessary component of Ad infection 
(Brüning et al. 2001,Wickham et al. 1993, Takayama 
et al. 1998).  
 One clear way to move forward has been to 
target the integrins found on the cancer cells. The 
ligand of αvβ3 and αvβ5 integrins was determined to be 
a tripeptide motif, RGD (Ruoslahti 1996). This RGD 
motif may bind to several integrins (Gamble et al. 
2010). The binding ability of RGD to a particular set 
of integrins is dependent upon several factors, includ-
ing but not limited to: 1) flanking region of the RGD 
sequence and 2) accessibility of binding sites. Experi-
ments have shown that different RGD motifs bind dif-
ferently to the same integrins. In an elaborate experi-
ment to determine which of seven previously reported 
RGD motifs bound and transduced both CAR positive 
and CAR negative cells the best, Nagel et al. deter-
mined that the RGD4C motif inserted into the HI-loop 
of fiber, the structure used by Dmitriev et al. (1998) 
performed better than the other six variations of RGD 
incorporation (Nagel et al. 2003). The results of their 
study also indicated that the RGD motif found on pen-
ton base, when placed into the HI-loop of fiber, does 
not bind as well as the RGD4C motif used by Dmitriev 
et al. Based on these data, we decided to use the 
RGD4C motif for our experiments as well.  
 Ads have been proposed as oncolytic virother-
apy agents. The ability of Ads to infect a wide range of 
cells, ability to replicate in dividing and non-dividing 
cells, and ability to incorporate a large amount of ma-
terial (i.e. therapeutic genes, imaging modalities) into 
their genomes underscored their potential utility as 
oncolytic agents. Discovery that the Ad primary recep-
tor, CAR, is decreased on the surfaces of several can-
cer cell types (Hemmi et al. 1998, Miller et al. 1998), 
including ovarian cancer cells (Kim et al. 2002), led to 
efforts to circumvent this problem. Scientists re-
sponded by altering Ad tropism with a tripeptide motif, 
Arginine-Glycine-Aspartate (RGD). Ad5lucRGD was 
created and found to have enhanced transduction of 
ovarian cancer cells and primary tumor tissues 
(Dmitriev et al. 1998). It was also noted that this virus 
is capable of successfully transducing ovarian cancer 
cells in vitro and patient ovarian cancer samples ex 
vivo in a CAR-independent manner (Dmitriev et al. 
1998). The ability to effectively transduce ovarian can-
cer cells by addition of the RGD4C motif was promis-
ing but left another concern, safety.   
 Replication selectivity is one way to enhance 
the safety of Ads that are to be used as therapeutic 
agents. To this end, scientists have made several at-
tempts to render Ads conditionally replicative by delet-
ing the E1A gene, modifying the E1A gene, or insert-
ing tumor specific promoters to regulate the E1A gene.  
The E1A proteins are necessary for viral replication 
and are the first to be produced following viral trans-
duction (Dyson & Harlow 1992, Flint & Shenk 1997). 
In normal viral replication, E1A protein binds to Rb, 
causing the release of Rb from its dimerization with 
E2F. This uncoupling leads to cellular transition from 
the G1/S checkpoint (Nevins 1992). Deletion of 24 
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Figure 5. SKOV3.Luc cells, which constitutively express 
luciferase, were used to determine if luciferase expression is 
indicative of amount of number of cells remaining alive 
following 10 days of infection with indicated CRAd. 
bases of the E1A gene resulting in loss of Rb binding 
site of E1A prevents cellular transition to S phase 
which results in the inability of virus to replicate in 
cells with a normal p16/Rb pathway (Fueyo et al. 
2000). Many cancer types, including ovarian cancer, 
do not have a normal p16/Rb pathway. In fact, two 
studies have shown that nearly 50% of ovarian carci-
nomas have a dysfunctional p16/Rb pathway 
(Yaginuma et al. 1997, Niederacher et al. 1999, Cor-
ney et al. 2008). This defect in the p16/Rb pathway in 
ovarian cancer cells that is not present in normal cells 
allows for cancer cell-selective replication of Δ24Ad5 
Figure 6. SKOV3.Luc cells (1.0 x 107 vp) were injected IP into the abdomen of female BALB/c nude mice. Mice were divided 
into groups (n=15) and each group was treated with CRAds (1.0 x 109 vp) or PBS on Days 0, 7, and 14. Abdominal tumors 
increased in size in mice from Day 0 to Day 35 as determined by detection of photons following IP injection of luciferase sub-
strate (A). Asterisk (*) indicates that all mice from PBS group had died by day 35 (with the exception of one outlier). Quantita-
tive analysis of photons emitted by abdominal tumors indicated an increased rate of growth of PBS-injected mice as compared 
with CRAd-injected mice (B). Asterisk (*) indicates that all mice from PBS group were dead by day 35 so data could not be 
generated for this group. Mice injected with ∆24Ad5 (p=0.0015), ∆24IXRGD (p=0.032), or ∆24FiberRGD (p=0.007) showed a 
significant increase in survival as compared to PBS-treated mice. ∆24DoubleRGD showed a non-significant (p=0.11) increase 
in survival versus PBS-treated mice. Survival of mice treated with each of the CRAds was similar (C). 
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CRAds (Fueyo et al. 2000). Δ24FiberRGD has been 
determined to be safe in cotton rats in a study designed 
to determine toxicity prior to use in clinical trials (Page 
et al. 2007). Both the safety and utility of 
Δ24FiberRGD were tested in a clinical trial to treat 
patients with advanced ovarian cancer (Kimball et al. 
2010).  
 Based on the above information, we endeav-
ored to engineer a virus, Δ24DoubleRGD, that selec-
tively replicates in cancer cells and also targets αvβ3 
and αvβ5 integrins, present on ovarian cancer cells, bet-
ter than the previously tested Δ24FiberRGD as evi-
denced by increased oncolytic ability. To this end, we 
successfully incorporated an RGD fusion protein into 
the pIX region of Δ24FiberRGD (Figure 1). We also 
created or amplified the other CRAds that were to be 
used as controls: Δ24, Δ24IXRGD, and 
Δ24FiberRGD.  Coomassie staining indicated that 
there were similar amounts of structural proteins pre-
sent in each of the CRAds (Figure 2A). This suggests 
that incorporation of an RGD motif at Fiber and fusion 
protein at pIX does not interfere with incorporation of 
major viral proteins into the Ad capsid. Western blot 
analysis for pIX indicates that the CRAds differentially 
incorporate pIX into their capsids based upon integra-
tion of the fusion protein (Figure 2B and C). Further 
validation of CRAd integrity indicated that Flag is pre-
sent on pIX from Δ24IXRGD and Δ24DoubleRGD 
(Figure 2C to D), the only CRAds that incorporate 
these motifs (Figure 1). This finding by both Western 
blot  and ELISA analyses validates incorporation of 
the fusion protein, containing RGD at the pIX locale, 
in  Δ24IXRGD and Δ24FiberRGD. The degradation 
products seen on the Western blot in the Δ24IXRGD 
sample and to a lesser degree in the Δ24DoubleRGD 
sample indicate that some amount of the modified pro-
tein may not have formed or folded properly. 
 Our data indicate differential binding of 
Δ24FiberRGD to αvβ3 and αvβ5 (Figure 3A to B) and 
that Δ24FiberRGD selectively binds to αvβ5 integrin, 
suggesting that the binding characteristics  of the RGD 
motif in the HI-loop may  be different from that of the 
RGD motif fused in pIX of Δ24IXRGD, which binds 
both αvβ3 and αvβ5 integrins. Moreover, we observed 
the interaction between the RGD motif of penton base 
and αvβ3 and αvβ5 integrins at a high concentration, 
supporting previous data that Ads utilize αvβ3 and αvβ5 
as secondary receptors (Nagel et al. 2003, Mathias et 
al. 1994, Goldman & Wilson 1995). Taken together, 
these data lead to the conclusion that modification of 
pIX using the RGD motif expands Ad5 tropism, and 
Δ24DoubleRGD and Δ24IXRGD are capable of bind-
ing not only αvβ5 but also αvβ3 integrins. 
 Cell viability assays comparing our 
Δ24DoubleRGD with Δ24FiberRGD suggest enhanced 
oncolysis of ovarian cancer cells infected with 
Δ24DoubleRGD in vitro (Figure 4A and B). This con-
clusion was corroborated by the decrease in luciferase 
activity of SKOV3.Luc cells following infection and 
CPE induction (Figure 5). We suspect that the en-
hanced oncolysis of SKOV3.Luc cells may be due to 
the ability of Δ24DoubleRGD to bind to both the αvβ3 
and αvβ5 integrins while ΔFiberRGD shows enhanced 
binding to αvβ5 preferentially. Similar cell killing abil-
ity of all CRAds tested in the orthotopic model of 
ovarian cancer in nude mice may be due to several fac-
tors (Figure 6A to C). While this model replicates the 
intraperitoneal setting of disease that is seen in ovarian 
cancer patients, the pre-existing Ad immunity which 
results in decreased oncolytic ability of Δ24 (Elkas et 
al. 1999) is not seen. Approximately 35% of patients 
in the US and Europe have pre-existing Ad immunity 
(Initiative IAV 2010). This fact gives Δ24FiberRGD 
its clinical advantage over Δ24Ad5, despite their simi-
lar cell killing abilities, because previously reported 
data indicate that the RGD motifs on Fiber protect the 
CRAd from the antibodies in the ascites found in the 
peritoneum of ovarian cancer patients (Elkas et al. 
1999, Blackwell et al. 2000, Stewart et al. 1997). Be-
cause we used a nude mouse model and were not able 
to pre-expose our mice to Ad5, we were unable to dis-
cern the differences between oncolytic ability of 
Δ2Ad5 versus Δ24FiberRGD nor differences between 
Δ24DoubleRGD and Δ24FiberRGD in this setting.  
 This vector is also a unique representation of 
the Ad5’s ability to target cells through a simultaneous 
expression of the RGD motif on different structural 
components  of the Ad capsid. Generation of this virus 
and verification of its ability to enhance cell killing 
versus a singly-modified virus is a proof of principle 
for the idea that modification of both pIX and Fiber 
may be used in conjunction to enhance the oncolytic 
efficacy of CRAds. Previous reports have indicated 
that modification of pIX with various motifs can result 
in enhanced CAR-deficient cell infectivity (Dmitriev et 
al. 2002), detection (Le et al. 2004), delivery of thera-
peutics (Li et al. 2005), shielding (Li et al. 2005, Hed-
ley et al. 2006), and even allow mosaic combinations 
of these modifications by heterologous incorporation 
into pIX (Kimball et al. 2009, Tang et al. 2008, 2009, 
Matthews et al. 2006). 
 In conclusion, our data shows enhanced onco-
lytic ability of Δ24DoubleRGD relative to  
Δ24FiberRGD in vitro but similar antitumor potency  
to that of  Δ24FiberRGD in an orthotopic model of 
ovarian cancer in nude mice. As the virotherapy field 
continues to advance, animal models that more closely 
resemble the pathophysiology  of human patients must 
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progress towards models that will allow scientists to 
discern between therapeutics that will or will not work 
and therapeutics that are or are not safe.   
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